These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15525873)

  • 1. Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy.
    Ambroisine ML; Milliez P; Nehme J; Pasquier AL; De Angelis N; Mansier P; Swynghedauw B; Delcayre C
    Diabetes Metab; 2004 Sep; 30(4):311-8. PubMed ID: 15525873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
    Takeda Y
    Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of aldosterone.
    Murin J
    Bratisl Lek Listy; 2005; 106(1):3-19. PubMed ID: 15869008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone and its blockade: a cardiovascular and renal perspective.
    Lahera V; Cachofeiro V; Balfagon G; Rodicio JL
    ScientificWorldJournal; 2006 Apr; 6():413-24. PubMed ID: 16604252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aldosterone and MR blockade on the brain and the kidney.
    Stier CT; Rocha R; Chander PN
    Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathophysiology of aldosterone in the cardiovascular system.
    Rocha R; Funder JW
    Ann N Y Acad Sci; 2002 Sep; 970():89-100. PubMed ID: 12381544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology.
    Delyani JA
    Kidney Int; 2000 Apr; 57(4):1408-11. PubMed ID: 10760075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
    Young MJ; Funder JW
    J Hypertens; 2002 Aug; 20(8):1465-8. PubMed ID: 12172301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor blockade in the protection of target organ damage.
    Mulatero P; Milan A; Williams TA; Veglio F
    Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):75-91. PubMed ID: 16529552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone: effects on the kidney and cardiovascular system.
    Briet M; Schiffrin EL
    Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone as a mediator in cardiovascular injury.
    Stier CT; Chander PN; Rocha R
    Cardiol Rev; 2002; 10(2):97-107. PubMed ID: 11895576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
    Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications].
    Bertocchio JP; Jaisser F
    Nephrol Ther; 2011 Jun; 7(3):139-47. PubMed ID: 21144811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone, mineralocorticoid receptor, and heart failure.
    Messaoudi S; Azibani F; Delcayre C; Jaisser F
    Mol Cell Endocrinol; 2012 Mar; 350(2):266-72. PubMed ID: 21784127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.
    Bertocchio JP; Warnock DG; Jaisser F
    Kidney Int; 2011 May; 79(10):1051-60. PubMed ID: 21412221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
    Goenka L; Padmanaban R; George M
    Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
    Jewell CW; Watson LE; Mock J; Dostal DE
    Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.